CERo Therapeutics (CEROW) Competitors $0.02 0.00 (-0.51%) As of 08/5/2025 02:46 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsShort InterestTrendsBuy This Stock CEROW vs. ATNFW, SXTPW, DRTSW, APLMW, BCTXW, CDIOW, CELUW, CINGW, CLNNW, and COEPWShould you be buying CERo Therapeutics stock or one of its competitors? The main competitors of CERo Therapeutics include 180 Life Sciences (ATNFW), 60 Degrees Pharmaceuticals (SXTPW), Alpha Tau Medical (DRTSW), Apollomics (APLMW), BriaCell Therapeutics (BCTXW), Cardio Diagnostics (CDIOW), Celularity (CELUW), Cingulate (CINGW), Clene (CLNNW), and Coeptis Therapeutics (COEPW). These companies are all part of the "biotechnology" industry. CERo Therapeutics vs. Its Competitors 180 Life Sciences 60 Degrees Pharmaceuticals Alpha Tau Medical Apollomics BriaCell Therapeutics Cardio Diagnostics Celularity Cingulate Clene Coeptis Therapeutics 180 Life Sciences (NASDAQ:ATNFW) and CERo Therapeutics (NASDAQ:CEROW) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment. Which has better earnings and valuation, ATNFW or CEROW? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio180 Life SciencesN/AN/AN/AN/AN/ACERo TherapeuticsN/AN/AN/AN/AN/A Is ATNFW or CEROW more profitable? Company Net Margins Return on Equity Return on Assets 180 Life SciencesN/A N/A N/A CERo Therapeutics N/A N/A N/A Does the media prefer ATNFW or CEROW? In the previous week, CERo Therapeutics had 1 more articles in the media than 180 Life Sciences. MarketBeat recorded 2 mentions for CERo Therapeutics and 1 mentions for 180 Life Sciences. 180 Life Sciences' average media sentiment score of 0.95 beat CERo Therapeutics' score of 0.01 indicating that 180 Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 180 Life Sciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CERo Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Summary180 Life Sciences and CERo Therapeutics tied by winning 1 of the 2 factors compared between the two stocks. Get CERo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CEROW and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CEROW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CEROW vs. The Competition Export to ExcelMetricCERo TherapeuticsBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$136.82M$5.59B$9.53BDividend YieldN/A3.74%4.73%4.14%P/E RatioN/A3.7528.9123.88Price / SalesN/A4,229.57445.5998.82Price / CashN/A13.1935.6858.35Price / BookN/A39.298.165.60Net IncomeN/A-$90.99M$3.25B$265.26M7 Day PerformanceN/A-0.62%1.17%-0.14%1 Month PerformanceN/A4.36%8.27%6.08%1 Year PerformanceN/A179.13%29.19%24.22% CERo Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CEROWCERo TherapeuticsN/A$0.02-0.5%N/A-35.3%$0.00N/A0.008News CoveragePositive NewsShort Interest ↑Gap DownATNFW180 Life SciencesN/A$0.01-1.5%N/A+38.2%$0.00N/A0.007SXTPW60 Degrees PharmaceuticalsN/A$0.06-4.4%N/A+143.7%$0.00$665.45K0.002Gap UpDRTSWAlpha Tau MedicalN/A$0.26+6.3%N/A+140.6%$0.00N/A0.0080Positive NewsGap DownAPLMWApollomicsN/A$0.03-7.6%N/A+106.4%$0.00N/A0.0059Positive NewsGap DownBCTXWBriaCell TherapeuticsN/A$0.04-12.8%N/A-79.9%$0.00N/A0.008Short Interest ↑Gap DownCDIOWCardio DiagnosticsN/A$0.01-1.4%N/A-67.6%$0.00$19.90K0.007Negative NewsShort Interest ↑CELUWCelularityN/A$0.06+20.0%N/A+143.9%$0.00$54.22M0.00220Positive NewsGap DownCINGWCingulateN/A$0.12-8.3%N/A+1,285.6%$0.00N/A0.0020Positive NewsCLNNWCleneN/A$0.04+31.7%N/A+30.0%$0.00$350K0.00100Positive NewsGap DownCOEPWCoeptis TherapeuticsN/A$0.03+15.9%N/A+24.9%$0.00$62.87K0.004Positive News Related Companies and Tools Related Companies ATNFW Competitors SXTPW Competitors DRTSW Competitors APLMW Competitors BCTXW Competitors CDIOW Competitors CELUW Competitors CINGW Competitors CLNNW Competitors COEPW Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CEROW) was last updated on 8/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOne stock to replace NvidiaInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredAltucher: $900 to $108,000? Trump’s “Great Gain” Is HereJames Altucher says two recent events could trigger a historic wealth shift—one driven by a radical Trump poli...Paradigm Press | Sponsored[Warning] Buffett Indicator hits new All-Time-HighWarren Buffett has leaned on one key indicator for decades—and it just hit an all-time high. That’s not bullis...Golden Portfolio | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CERo Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CERo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
